Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$402.6 million.
- Dianthus Therapeutics' Enterprise Value fell 4321.6% to -$402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$402.6 million, marking a year-over-year decrease of 4321.6%. This contributed to the annual value of -$275.2 million for FY2024, which is 5844.13% down from last year.
- Per Dianthus Therapeutics' latest filing, its Enterprise Value stood at -$402.6 million for Q3 2025, which was down 4321.6% from -$257.4 million recorded in Q2 2025.
- Dianthus Therapeutics' Enterprise Value's 5-year high stood at -$52.9 million during Q1 2023, with a 5-year trough of -$402.6 million in Q3 2025.
- For the 4-year period, Dianthus Therapeutics' Enterprise Value averaged around -$211.1 million, with its median value being -$189.9 million (2023).
- Per our database at Business Quant, Dianthus Therapeutics' Enterprise Value soared by 6622.37% in 2023 and then crashed by 61280.08% in 2024.
- Quarter analysis of 4 years shows Dianthus Therapeutics' Enterprise Value stood at -$75.5 million in 2022, then plummeted by 130.12% to -$173.7 million in 2023, then tumbled by 58.44% to -$275.2 million in 2024, then plummeted by 46.28% to -$402.6 million in 2025.
- Its last three reported values are -$402.6 million in Q3 2025, -$257.4 million for Q2 2025, and -$263.2 million during Q1 2025.